Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding the Large-Scale Exercise of the 70th Series Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)

With respect to the 70th Series of Stock Acquisition Rights, 8,024,000 shares were delivered from 2 November to 5 November 2026, and the number of exercised stock acquisition rights increased by 80,240. The balance of unexercised rights was 328,460 as of 5 November.

Worth reading
48Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
8024000
shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Report on the Exercise Status (Large-Scale Exercise) of the 70th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)

発行・処分する株式数8,024,000Shares

8,024,000 new shares (no treasury shares transferred)

Intended allottee
EVO FUND (allottee of the previously issued stock acquisition rights)
Terms of the stock acquisition rights
Exercise price
¥44 on 2 November, ¥43 on 4 November, and ¥42 on 5 November. The exercise price is subject to an adjustment clause, but the lower limit of the adjustment is Not disclosed
Number of Stock Acquisition Rights
Total issued: 480,000 rights. Unexercised balance at the end of the previous month: 408,700 rights; unexercised balance as of 5 November: 328,460 rights
Most recent equity financing
Timing 2 September 2026 / Type Issuance of the 70th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause), allocated to EVO FUND / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReport on the Exercise Status (Large-Scale Exercise) of the 70th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)
Number of shares to be issued or disposed of8,024,000 new shares (no treasury shares transferred)
Intended allotteeEVO FUND (allottee of the previously issued stock acquisition rights)
Total number of issued shares87,378,960 shares (as of the end of the month preceding the relevant month) → Not disclosed
Exercise price¥44 on 2 November, ¥43 on 4 November, and ¥42 on 5 November. The exercise price is subject to an adjustment clause, but the lower limit of the adjustment is Not disclosed
Number of Stock Acquisition RightsTotal issued: 480,000 rights. Unexercised balance at the end of the previous month: 408,700 rights; unexercised balance as of 5 November: 328,460 rights
Most recent equity financingTiming 2 September 2026 / Type Issuance of the 70th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause), allocated to EVO FUND / Amount Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The exercise status is being reported because a large-scale exercise occurred. No additional reason is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Large-Scale Exercise of the 70th Series Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause) | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori